ArticleJournal of translational medicine2026
PIEZO1 mediates orthodontic tension force-induced alveolar bone remodeling via the Ca²⁺/YAP-TAZ pathway in periodontal ligament stem cells.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPeriodontal ligament stem cells (PDLSCs) orchestrate alveolar bone remodeling during orthodontic tooth movement (OTM), yet the molecular mechanism translating tension force into coupled osteogenic and anti-osteoclastic responses remains elusive. This study aimed to define the dual mechanosensitive role of PIEZO1 in PDLSCs for simultaneously promoting osteogenesis and suppressing osteoclastogenesis via the Ca²⁺/YAP-TAZ/OPG-RANKL signaling axis.
methodsHuman PDLSCs were isolated, characterized for mesenchymal markers, and exposed to cyclic tension (10% strain, 0.5 Hz) using a Flexcell system. PIEZO1 was inhibited using GsMTx4 or siRNA, and Ca²⁺ flux was analyzed by live-cell confocal microscopy. Osteogenic (RUNX2, OSX), osteoclastic (RANKL, OPG), and YAP/TAZ signaling markers were assessed using RT-qPCR and Western blot. For in vivo validation, a rat OTM model was established using 40-g NiTi springs. Tooth movement and tension-side alveolar bone remodeling were quantified by micro-CT, while osteogenic and osteoclastic activities were evaluated through immunohistochemistry and TRAP staining.
resultsTension force activated PIEZO1 channels, triggering rapid Ca²⁺ influx and subsequent nuclear accumulation of YAP/TAZ. YAP/TAZ activation transcriptionally upregulated RUNX2 and OSX, concurrently reprogramming the PDLSC secretome to favor Osteoprotegerin (OPG) dominance over RANKL, significantly reducing the RANKL/OPG ratio and thus suppressing osteoclast differentiation. Pharmacological inhibition of PIEZO1 (GsMTx4) or genetic knockdown abrogated Ca²⁺ influx, prevented YAP/TAZ nuclear translocation, and disrupted the RANKL/OPG balance, thereby uncoupling osteogenesis from osteoclast suppression both in vitro and in vivo.
conclusionsThis study defines a fundamental mechanotransduction cascade initiated by PIEZO1, wherein Ca²⁺ influx mobilizes YAP/TAZ nuclear translocation to transcriptionally activate osteogenic differentiation and reprogram anti-osteoclastic secretory profiles. Deciphering this mechanocode nominates PIEZO1 as a promising therapeutic target for recalibrating bone remodeling balance and mitigating pathological bone loss during orthodontic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.